Friday, March 9, 2018

Horticulture terapy

Caregivers, and healthcare professionals,here is some great information

Here is a great dementia resource for caregivers and healthcare professionals,

Your residents will love the Amazon Kindle Fire

Here is information on being the best caregiver you can be

Here is a way for nurses administrators, social workers and other health care  professionals to get an easyceu or two

Follow alzheimersideas on twitter

The Dementia Caregiver's Little Book of Hope [Kindle Edition]


  • CTV

Gardening helps seniors with Alzheimer's grow fresh plants & better thinking. Overcome short-term memory loss by bringing back good feelings and lost moments. See purposeful, creative work help overcome dementia's limitations.

Wednesday, March 7, 2018

Why Namzaric for dementia

Caregivers, and healthcare professionals,here is some great information

Here is a great dementia resource for caregivers and healthcare professionals,

Your residents will love the Amazon Kindle Fire

Here is information on being the best caregiver you can be

Here is a way for nurses administrators, social workers and other health care  professionals to get an easyceu or two

Follow alzheimersideas on twitter

The Dementia Caregiver's Little Book of Hope [Kindle Edition]

Actavis plc


Namazaric for dementia comes in a convenient, extended-release capsule. It conveniently combines today's 2 most popular drugs for Alzheimer's. Learn about easy-to-manage Namazaric.



Namzaric is a fixed-dose combination (FDC) of Namenda (known generically as memantine hydrochloride) and Aricept (known generically as donepezilhydrochloride). Namzaric was approved for the treatment of moderate to severe dementia of the Alzheimer's type.

Continued below Namazaric's video ad...

Advantages

The benefits of Namzaric over current treatments include:
  1. Extended release formulation: This means that the medication is in a capsule that releases it to the body slowly, over the course of the day. This can sometimes make it easier for the body to absorb, with fewer side effects, and with more consistent results throughout the day.
  2. One pill: The pill regimen for seniors is often difficult and complex. The fewer pills a person needs to remember to take, and the fewer times per day they need to do so, the better.
  3. Capsule can be opened: Namzaric comes in an easy-to-open capsule, making it simple to sprinkle the medication over or into food.

Aricept + Namenda (Donepezil+Memantine)

Memantine is the generic active ingredient in the currently marketed NAMENDA®, which is indicated for the treatment of moderate to severe dementia of the Alzheimer's type. Donepezil is the active ingredient in ARICEPT®, which is indicated for the treatment of mild to severe dementia of the Alzheimer's type.
Brand NameGeneric NameType
AriceptdonepezilAChEI (Acetylcholinesterase Inhibitor)
NamendamemantineNMDA Receptor Antagonist

"Namzaric combines, in one capsule, two complementary therapeutic agents which are often co-prescribed as approximately 70% of Namenda XR patients are also on AChEI therapy. Both Namenda XR and donepezil have proven efficacy and safety, for the treatment of moderate to severe Alzheimer's disease. Additionally, data has shown that combination therapy with Namenda XR and an AChEI demonstrated greater improvement in cognition and global function verses an AChEI alone," said David Nicholson, Actavis Senior Vice President, Global Brands R&D. "Along with our partner Adamas, we are proud that this important therapy will provide a convenient and innovative treatment option for Alzheimer's patients and caregivers that reduces the number of capsules they are required to take each day for the treatment of this devastating disease."

"We are excited about the approval of Namzaric — the first fixed-dose combination of extended-release memantine and donepezil — and look forward to its launch by Actavis in 2015," said Gregory T. Went, Ph.D., Chairman and CEO of Adamas Pharmaceuticals, Inc. "Namzaric is also the first FDA-approved FDC product to emerge from Adamas' platform for modifying the pharmacokinetic profiles of approved drugs, and we look forward to developing additional new treatments for individuals with serious neurological CNS disorders."

Namzaric = Memantine + Donepezil

Namzaric, formerly known as MDX-8704, is a once-daily oral capsule for patients currently taking memantine (10 mg twice daily or 28 mg extended-release once-daily) and donepezil 10 mg. In addition, the capsules can be opened to allow the contents to be sprinkled on food to facilitate dosing for patients who may have difficulty swallowing.

"When determining therapies for my patients in the moderate to severe stages of Alzheimer's disease, I consider the therapy's effectiveness, safety profile and its ease of administration. The FDA's approval of Namzaric offers a new therapeutic option that provides patients a fixed-dose combination of two treatments often prescribed together, in one capsule," said Gustavo Alva, MD, Neuropsychiatrist and Medical Director at ATP Clinical Research in Costa Mesa, CA and volunteer faculty member at University of California, Irvine.

Namzaric is available in two dosage strengths, 28/10 mg (memantine extended release/donepezil) and 14/10mg (memantine extended release/donepezil) for patients with severe renal impairment. Actavis and Adamas collaborated on the development of the fixed-dose combination and Actavis will have exclusive U.S. commercialization rights, while Adamas will retain exclusive commercialization rights outside of the U.S. Actavis expects to launch Namzaric in the U.S. in the second quarter of 2015.

Results from the Clinical Trials

The efficacy and safety of the coadministration of memantine HCl extended release and acetylcholinesterase inhibitors (AChEIs), including donepezil HCl, was based on the results of a randomized, double-blind, placebo-controlled trial of 677 outpatients on a stable dose of AChEIs. The clinical study was not conducted with Namazaric; however, bioequivalence of Namazaric with coadministered memantine HCl extended release and donepezil HCl was demonstrated. Approximately 68% of the patients randomized to receive either memantine HCl extended release 28 mg or placebo were taking donepezil as the AchEI at Baseline and throughout the study. The results of this study, demonstrated statistically significant improvement in cognition and global function for patients treated with NAMENDA XR 28 mg plus an AChEI compared to placebo plus an AChEI.

The most commonly observed adverse reactions seen with memantine hydrochloride extended-release in patients with moderate to severe Alzheimer's disease, defined as those occurring at a frequency of at least 5% in the memantine hydrochloride extended-release group and at a higher frequency than placebo, were headache, diarrhea, and dizziness. 

Help your loved one receive a 30-day trial supply of NAMZARIC at $0 out-of-pocket cost with Namzaric's Trial Offer. Click here.

About Adamas Pharmaceuticals Adamas Pharmaceuticals, Inc. is a specialty pharmaceutical company driven to improve the lives of those affected by chronic disorders of the central nervous system. The company achieves this by modifying the pharmacokinetic profiles of approved drugs to create novel therapeutics for use alone or in fixed-dose combination products. Adamas is currently developing its lead wholly-owned product candidate, ADS-5102, for a complication of Parkinson's disease known as levodopa-induced dyskinesia, or LID, and is evaluating other potential indications. The company's portfolio also includes two approved products developed with Forest. The first is a fixed-dose combination product, Namzaric, and the second is a controlled-release product, Namenda XR®. Forest markets both products in the United States under an exclusive license from Adamas. For more information, please visit www.adamaspharma.com.

About Actavis Actavis plc (NYSE:ACT), headquartered in Dublin, Ireland, is a unique specialty pharmaceutical company focused on developing, manufacturing and commercializing high quality affordable generic and innovative branded pharmaceutical products for patients around the world.

Actavis markets a broad portfolio of branded and generic pharmaceuticals and develops innovative medicines for patients suffering from diseases principally in the central nervous system, gastroenterology, women's health, urology, cardiovascular, respiratory and anti-infective therapeutic categories. The Company is an industry leader in product research and development, with one of the broadest brand development pipelines in the pharmaceutical industry, and a leading position in the submission of generic product applications. Actavis has commercial operations in more than 60 countries and operates more than 30 manufacturing and distribution facilities around the world.

For more information, visit Actavis' website at www.actavis.com.

SOURCE: Actavis plc


Monday, March 5, 2018

Dementia and sleep

Caregivers, and healthcare professionals,here is some great information

Here is a great dementia resource for caregivers and healthcare professionals,

Your residents will love the Amazon Kindle Fire

Here is information on being the best caregiver you can be

Here is a way for nurses administrators, social workers and other health care  professionals to get an easyceu or two

Follow alzheimersideas on twitter

The Dementia Caregiver's Little Book of Hope [Kindle Edition]

Deep sleep refreshes. Too little deep sleep and sleep apnea can trigger brain changes linked to vascular dementia. Learn what happens. See how you can prevent it. 




MINNEAPOLIS
 – People who have sleep apnea or spend less time in deep sleep may be more likely to have changes in the brain that are associated with dementia, according to a new study published in the December 2014 online issue of Neurology®, the medical journal of the American Academy of Neurology. 

Researchers studied people who don’t have as much oxygen in their blood during sleep, which occurs with sleep apnea and conditions such as emphysema. 

The study found such people are more likely to have tiny abnormalities in brain tissue, called micro infarcts, than people with higher levels of oxygen in the blood. 

These abnormalities are associated with the development of vascular dementia. 

Continued below video...


In addition, people who spent less time in deep sleep, called slow wave sleep, were more likely to have loss of brain cells than people who spent more time in slow wave sleep. Slow wave sleep is important in processing new memories and remembering facts. People tend to spend less time in slow wave sleep as they age. Loss of brain cells is also associated with Alzheimer’s disease and dementia. 

For the study, 167 Japanese American men had sleep tests conducted in their homes when they were an average age of 84. All were followed until they died an average of six years later, and autopsies were conducted on their brains to look for micro infarcts, loss of brain cells, the plaques and tangles associated with Alzheimer’s disease and Lewy bodies found in Lewy body dementia. 

The researchers divided the participants into four groups based on the percentage of time spent with lower than normal blood oxygen levels during sleep, with the lowest group spending 13 percent of their time or less with low oxygen levels and the highest group spending 72 to 99 percent of the night with low oxygen levels. Each group had 41 or 42 men. Of the 41 men in the lowest group, four had micro infarcts in the brain, while 14 of the 42 men in the highest group had the abnormalities, making them nearly four times more likely to have brain damage



Previous studies have also shown a link between sleep stages and dementia. For this study, the participants were again divided into four groups based on the percentage of the night spent in slow wave sleep. Of the 37 men who spent the least time in slow wave sleep, 17 had brain cell loss, compared to seven of the 38 men who spent the most time in slow wave sleep. 

The results remained the same after adjusting for factors such as smoking and body mass index and after excluding participants who had died early in the follow-up period and those who had low scores on cognitive tests at the beginning of the study. 


“These findings suggest that low blood oxygen levels and reduced slow wave sleep may contribute to the processes that lead to cognitive decline and dementia,” said study author Rebecca P. Gelber, MD, DrPH, of the VA Pacific Islands Health Care System and the Pacific Health Research and Education Institute in Honolulu, Hawaii. “More research is needed to determine how slow wave sleep may play a restorative role in brain function and whether preventing low blood oxygen levels may reduce the risk of dementia.” 

Gelber noted that a previous study showed that use of a continuous positive airway pressure machine (CPAP) for obstructive sleep apnea may improve cognition, even after dementia has developed. 

There was no association between the sleep measures and the level of plaques and tangles. 

For the United States NIH Infograph on getting better sleep, see:
Sleep Disorders & Insufficient Sleep: Improving Health through Research 

MORE INFORMATION:

The study was supported by the National Institute on Aging, Alzheimer’s Association, Hawaii Community Foundation and Department of Veterans Affairs Pacific Islands Health Care System. To learn more about sleep and brain health, please visit www.aan.com/patients.

The American Academy of Neurology, an association of more than 28,000 neurologists and neuroscience professionals, is dedicated to promoting the highest quality patient-centered neurologic care. A neurologist is a doctor with specialized training in diagnosing, treating and managing disorders of the brain and nervous system such as Alzheimer’s disease, stroke, migraine, multiple sclerosis, concussion, Parkinson’s disease and epilepsy.

Saturday, March 3, 2018

Calm agitation in Alzheimer's

Caregivers, and healthcare professionals,here is some great information

Here is a great dementia resource for caregivers and healthcare professionals,

Your residents will love the Amazon Kindle Fire

Here is information on being the best caregiver you can be

Here is a way for nurses administrators, social workers and other health care  professionals to get an easyceu or two

Follow alzheimersideas on twitter

The Dementia Caregiver's Little Book of Hope [Kindle Edition]

Johns Hopkins Medicine



The antidepressant drug citalopram, also sold under the brand names Celexa and Cipramil, significantly relieved agitation in Alzheimer’s. Learn about the benefits and side-effects. 




The antidepressant drug citalopram, sold under the brand names Celexa and Cipramil and also available as a generic medication, significantly relieved agitation in a group of patients with Alzheimer's disease. In lower doses than those tested, the drug might be safer than antipsychotic drugs currently used to treat the condition, according to results of a clinical trial led by Johns Hopkins researchers that included seven other academic medical centers in the United States and Canada.
For the study, reported in the Feb. 19 issue of the Journal of the American Medical Association, Constantine Lyketsos, M.D., M.H.S., and his colleagues recruited 186 patients with Alzheimer's who showed a collection of symptoms including emotional distress, excessive movement, aggression, disruptive irritability and disinhibition. 

None experienced adequate symptom relief with non-medical therapies, and some experienced failed treatment with antipsychotic drugs. Though antipsychotics are often used as first-line medications for Alzheimer's-related agitation, they significantly increase the risk of strokes, heart attacks and death, Lyketsos says.

At the start of the study, patients also underwent tests to define the extent of their agitation, memory and other cognitive skills, and their caregivers' stress levels, a factor strongly linked to the well-being of those with Alzheimer's. 

The patients were then separated into two groups. For the next nine weeks, about half took increasing doses of citalopram that peaked at 30 milligrams per day, and the rest took an identical-looking placebo.

At the end of the study period, the same set of tests was given, along with electrocardiograms. The study drug is linked to adverse effects on heart function, including irregular heartbeat, a harbinger of a heart attack.
Results showed that patients on the drug had significant relief from their agitation symptoms, Lyketsos says. In one measure of agitation, about 40 percent of patients who took citalopram had "considerable relief," compared to 26 percent of patients who took the placebo. The caregivers for these patients reported less stress.

However, patients on the drug were also more likely to have slightly decreased cognitive function. "It was not huge, but measureable," says Lyketsos, director of the Johns Hopkins Memory and Alzheimer's Treatment Center and director of the Department of Psychiatry at Johns Hopkins Bayview Medical Center. "That introduces a tradeoff."
More concerning, he adds, is that patients on citalopram had longer QTc intervals, a measure of abnormal heart function that increases the risk of heart attacks. However, Lyketsos says, antipsychotic medications also used to treat agitation increase heart attack risk as well, perhaps even more substantially.
Lyketsos and his colleagues hope to test if a lower dose of citalopram might be just as effective in treating Alzheimer's-related agitation with less risk for cognition and heart function. In the meantime, he says, the drug offers an alternative to antipsychotics.
"If the agitation is not responding to non-medication treatments and your patient's agitation isn't improving, there are no great options," Lyketsos says. "But here's another medication choice that might be safer than other medications and seems to be just as effective


Journal Reference:
  1. Anton P. Porsteinsson, Lea T. Drye, Bruce G. Pollock, D. P. Devanand, Constantine Frangakis, Zahinoor Ismail, Christopher Marano, Curtis L. Meinert, Jacobo E. Mintzer, Cynthia A. Munro, Gregory Pelton, Peter V. Rabins, Paul B. Rosenberg, Lon S. Schneider, David M. Shade, Daniel Weintraub, Jerome Yesavage, Constantine G. Lyketsos. Effect of Citalopram on Agitation in Alzheimer Disease. JAMA, 2014; 311 (7): 682 DOI: 10.1001/jama.2014.93
More Information:
This research was supported by grants from the National Institutes of Health’s National Institute on Aging and National Institute of Mental Health (R01AG031348 and P50AG05142).
In addition to Lyketsos, other Johns Hopkins researchers involved in this study include Lea T. Drye, Ph.D.; Constantine Frangakis, Ph.D.; Christopher Marano, M.D.; Curtis L. Meinert, Ph.D.; Cynthia A. Munro, Ph.D.; Peter V. Rabins, M.D.; Paul B. Rosenberg, M.D.; and David M. Shade, J.D.
Along with Johns Hopkins, the other medical centers involved in the clinical trial include Columbia University, the Medical University of South Carolina, Stanford University, the University of Pennsylvania, the University of Rochester, the University of Southern California and the University of Toronto.
For more information:
Johns Hopkins Medicine (JHM), headquartered in Baltimore, Maryland, is a $6.7 billion integrated global health enterprise and one of the leading health care systems in the United States. JHM unites physicians and scientists of the Johns Hopkins University School of Medicine with the organizations, health professionals and facilities of The Johns Hopkins Hospital and Health System. JHM's vision, “Together, we will deliver the promise of medicine,” is supported by its mission to improve the health of the community and the world by setting the standard of excellence in medical education, research and clinical care. Diverse and inclusive, JHM educates medical students, scientists, health care professionals and the public; conducts biomedical research; and provides patient-centered medicine to prevent, diagnose and treat human illness. JHM operates six academic and community hospitals, four suburban health care and surgery centers, and more than 30 primary health care outpatient sites. The Johns Hopkins Hospital, opened in 1889, was ranked number one in the nation for 21 years in a row by U.S. News & World Report.

Thursday, March 1, 2018

Brain-Beginning of Alzheimer's

Caregivers, and healthcare professionals,here is some great information

Here is a great dementia resource for caregivers and healthcare professionals,

Your residents will love the Amazon Kindle Fire

Here is information on being the best caregiver you can be

Here is a way for nurses administrators, social workers and other health care  professionals to get an easyceu or two

Follow alzheimersideas on twitter

The Dementia Caregiver's Little Book of Hope [Kindle Edition]


Source:


Columbia University Medical Center, via Newswise.

ROOTS OF ALZHEIMER'S: 

Columbia University researchers have pinpointed 3 discoveries about Alzheimer's:

  • Where it starts
  • Why it starts there
  • How it spreads.
Learn why this can help researchers treat Alzheimer's sooner and better. 




Using high-resolution functional MRI (fMRI) imaging in patients with Alzheimer's disease and in mouse models of the disease, Columbia University Medical Center (CUMC) researchers have clarified three fundamental issues about Alzheimer's: where it starts, why it starts there, and how it spreads. In addition to advancing understanding of Alzheimer's, the findings could improve early detection of the disease, when drugs may be most effective. The study was published today in the online edition of the journalNature Neuroscience.


Alzheimer's disease starts in the entorhinal cortex (yellow). Using fMRI in mouse (left) and human (right) brains, the researchers provide evidence that the disease spreads from the entohrinal cortex (yellow) to other cortical regions (red) -- the perirhinal cortex and posterior parietal cortex. (Credit: Usman Khan/lab of Scott A. Small, MD, Columbia University Medical Center.)

"It has been known for years that Alzheimer's starts in a brain region known as the entorhinal cortex," said co-senior author Scott A. Small, MD, Boris and Rose Katz Professor of Neurology, professor of radiology, and director of the Alzheimer's Disease Research Center. "But this study is the first to show in living patients that it begins specifically in the lateral entorhinal cortex, or LEC. The LEC is considered to be a gateway to the hippocampus, which plays a key role in the consolidation of long-term memory, among other functions. If the LEC is affected, other aspects of the hippocampus will also be affected."

The study also shows that, over time, Alzheimer's spreads from the LEC directly to other areas of the cerebral cortex, in particular, the parietal cortex, a brain region involved in various functions, including spatial orientation and navigation. The researchers suspect that Alzheimer's spreads "functionally," that is, by compromising the function of neurons in the LEC, which then compromises the integrity of neurons in adjoining areas.

A third major finding of the study is that LEC dysfunction occurs when changes in tau and amyloid precursor protein (APP) co-exist. "The LEC is especially vulnerable to Alzheimer's because it normally accumulates tau, which sensitizes the LEC to the accumulation of APP. Together, these two proteins damage neurons in the LEC, setting the stage for Alzheimer's," said co-senior author Karen E. Duff, PhD, professor of pathology and cell biology (in psychiatry and in the Taub Institute for Research on Alzheimer's Disease and the Aging Brain) at CUMC and at the New York State Psychiatric Institute.

In the study, the researchers used a high-resolution variant of fMRI to map metabolic defects in the brains of 96 adults enrolled in the Washington Heights-Inwood Columbia Aging Project (WHICAP). All of the adults were free of dementia at the time of enrollment.

"Dr. Richard Mayeux's WHICAP study enables us to follow a large group of healthy elderly individuals, some of whom have gone on to develop Alzheimer's disease," said Dr. Small. "This study has given us a unique opportunity to image and characterize patients with Alzheimer's in its earliest, preclinical stage."

The 96 adults were followed for an average of 3.5 years, at which time 12 individuals were found to have progressed to mild Alzheimer's disease. An analysis of the baseline fMRI images of those 12 individuals found significant decreases in cerebral blood volume (CBV) -- a measure of metabolic activity -- in the LEC compared with that of the 84 adults who were free of dementia.

A second part of the study addressed the role of tau and APP in LEC dysfunction. While previous studies have suggested that entorhinal cortex dysfunction is associated with both tau and APP abnormalities, it was not known how these proteins interact to drive this dysfunction, particularly in preclinical Alzheimer's.

To answer this question, explained first author Usman Khan, an MD-PhD student based in Dr. Small's lab, the team created three mouse models, one with elevated levels of tau in the LEC, one with elevated levels of APP, and one with elevated levels of both proteins. The researchers found that the LEC dysfunction occurred only in the mice with both tau and APP.

The study has implications for both research and treatment. "Now that we've pinpointed where Alzheimer's starts, and shown that those changes are observable using fMRI, we may be able to detect Alzheimer's at its earliest preclinical stage, when the disease might be more treatable and before it spreads to other brain regions," said Dr. Small. In addition, say the researchers, the new imaging method could be used to assess the efficacy of promising Alzheimer's drugs during the disease's early stages.

The paper is titled, "Molecular drivers and cortical spread of lateral entorhinal cortex dysfunction in preclinical Alzheimer's disease." The other contributors are Li Liu, Frank Provenzano, Diego Berman, Caterina Profaci, Richard Sloan and Richard Mayeux, all at CUMC.

The study was supported by grants from National Institutes of Health (AG034618, AG025161, AG07232, AG037212, NS074874, and HL094423.



Journal Reference:
  1. Usman A Khan, Li Liu, Frank A Provenzano, Diego E Berman, Caterina P Profaci, Richard Sloan, Richard Mayeux, Karen E Duff, Scott A Small. Molecular drivers and cortical spread of lateral entorhinal cortex dysfunction in preclinical Alzheimer's disease. Nature Neuroscience, 2013; DOI: 10.1038/nn.3606

Tuesday, February 27, 2018

Can robot change Alzheimer's care

Caregivers, and healthcare professionals,here is some great information

Here is a great dementia resource for caregivers and healthcare professionals,

Your residents will love the Amazon Kindle Fire

Here is information on being the best caregiver you can be

Here is a way for nurses administrators, social workers and other health care  professionals to get an easyceu or two

Follow alzheimersideas on twitter

The Dementia Caregiver's Little Book of Hope [Kindle Edition]



Will Ludwig the Robot revolutionize Alzheimer's care around the world? Developed by the University of Toronto, see how Ludwig could help patients with Alzheimer's and dementia. 




As the dementia population around the world grows, healthcare systems are being forced to adapt. Already on the case are Frank Rudzicz, a computer scientist at the University of Toronto and the Toronto Rehabilitation Institute, and his two-foot-tall robotic boy Ludwig, which is powered by machine learning. 

Long passionate about robotics, Rudzicz determined during college that he could have the biggest impact on the field and artificial intelligence if he focused on natural language processing. The field touches many areas of AI, from human interaction and learning to developing knowledge of the world. 


Working on his doctoral project on speech recognition for people with cerebral palsy, Rudzicz learned what machine learning could accomplished in the clinical domain. So, he began looking for opportunities to apply his work in other healthcare scenarios, as well. 

He jumped into the cause, assembling a team at the University of Toronto and Toronto Rehabilitation Institute that started by developing a sort of diagnostic software for dementia, using speech as an input. 

“Language can provide a very deep and accurate lens as to the speaker’s cognitive emotional state, so we started there,” Rudzicz said. “But to be engaging, and to assist people when nurses or caregivers aren’t present, I wanted to develop something a bit more personal.”

What’s Important Is What’s Inside

So Rudzicz and his team decided to build a robot. The result of their efforts is Ludwig, which is being pilot tested at a long-term care facility in Toronto. While Ludwig isn’t the most impressive robot physically speaking, the machine learning algorithms running inside of him, which were trained on NVIDIA TITAN X GPUs, enable him to engage patients in conversation and analyze speech patterns to help assess each patient’s state. 

“We are focusing almost entirely on the software, and have had some success in showing that breakdowns in communication, which are very common in dementia, can be identified by using speech input and neural network models,” Rudzicz said. 

Patients have been signing up to participate in the pilot, and data collection is underway.

Advancing Human-Computer Interaction

Once the pilot is completed, Rudzicz said the next steps will be to further refine the software, and put GPUs to work again building a deep learning-powered neural network that would enable Ludwig to refocus conversations that get off track. Eventually, he has his eye on commercializing Ludwig, but he said that’s probably a few years away. 

In the meantime, he’s zeroed in on establishing the software inside Ludwig as a driving force behind human-computer interaction going forward, particularly in the dementia-treatment realm. 

“We hope that a key outcome of our current pilot will be a measure of how people with dementia feel about interacting with robots, which itself will guide our thinking going forward,” he said. “If the whole community can get interaction right, then products like Google Home and Amazon Echo will become much more entrenched.” 


Ludwick the Robot

Sunday, February 25, 2018

Causes of sundowning

Caregivers, and healthcare professionals,here is some great information

Here is a great dementia resource for caregivers and healthcare professionals,

Your residents will love the Amazon Kindle Fire

Here is information on being the best caregiver you can be

Here is a way for nurses administrators, social workers and other health care  professionals to get an easyceu or two

Follow alzheimersideas on twitter

The Dementia Caregiver's Little Book of Hope [Kindle Edition]


The Ohio State University, 

In "SUNDOWNING SYNDROME," people with dementia show high levels of anxiety, agitation, overactivity and delirium. It typically occurs in late afternoon and evening, before their normal time to go to bed. Learn how brain biology explains “sundowning.” 




COLUMBUS, Ohio – Valuable research provides the best evidence to date that the late-day anxiety and agitation sometimes seen in older institutionalized adults, especially those with dementia, has a biological basis in the brain.

The findings could help explain “sundowning,” a syndrome in which older adults show high levels of anxiety, agitation, general activity and delirium in late afternoon and evening, before they would normally go to bed.

“It’s a big problem for caregivers.  Patients can get aggressive and very disruptive,” said Tracy Bedrosian, lead author of the study and a doctoral student in neuroscience at Ohio State University.

“There have been a few clinical studies documenting sundowning, but until now there hasn’t been research in animals to see what’s going on in the brain to explain this.”


Blog Flux Directory
alzheimersideas - whereIstand.com

Fitness is important in dementia prevention. Click below for more info